(Q43869831)

English

Utility of the daily prospective National Institute of Mental Health Life-Chart Method (NIMH-LCM-p) ratings in clinical trials of bipolar disorder

scientific article published in January 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Utility of the daily prospective National Institute of Mental Health Life-Chart Method (NIMH-LCM-p) ratings in clinical trials of bipolar disorder (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

0 references

bipolar disorder

1 reference

based on heuristic

inferred from title

Gabriele S. Leverich

5

object named as

Gabriele S Leverich

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

6

object named as

Robert M Post

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Kirk D Denicoff

1

object named as

Kirk D Denicoff

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

author name string

S Omar Ali

2

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Ann B Sollinger

3

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Earlian E Smith-Jackson

4

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

publication date

1 January 2002

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Depression and Anxiety

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

1-9

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

An Inventory for Measuring Depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.1078

21 January 2018

Preliminary evidence of the reliability and validity of the prospective life-chart methodology (LCM-p).

1 reference

https://api.crossref.org/works/10.1002%2FDA.1078

21 January 2018

Validation of the prospective NIMH-Life-Chart Method (NIMH-LCM-p) for longitudinal assessment of bipolar illness.

1 reference

https://api.crossref.org/works/10.1002%2FDA.1078

21 January 2018

A diagnostic interview: the schedule for affective disorders and schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2FDA.1078

21 January 2018

The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance

1 reference

https://api.crossref.org/works/10.1002%2FDA.1078

21 January 2018

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.1078

21 January 2018

Ultra-rapid and ultradian cycling in bipolar affective illness

1 reference

https://api.crossref.org/works/10.1002%2FDA.1078

21 January 2018

Statistical approaches to trial durations in episodic affective illness.

1 reference

https://api.crossref.org/works/10.1002%2FDA.1078

21 January 2018

Graphic representation of the life course of illness in patients with affective disorder.

1 reference

https://api.crossref.org/works/10.1002%2FDA.1078

21 January 2018

A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala-kindled seizures

1 reference

https://api.crossref.org/works/10.1002%2FDA.1078

21 January 2018

Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP.

1 reference

https://api.crossref.org/works/10.1002%2FDA.1078

21 January 2018

A rating scale for mania: reliability, validity and sensitivity

1 reference

https://api.crossref.org/works/10.1002%2FDA.1078

21 January 2018

Recurrent brief depression: a new subtype of affective disorder

1 reference

https://api.crossref.org/works/10.1002%2FDA.1078

21 January 2018

The emerging epidemiology of hypomania and bipolar II disorder

1 reference

https://api.crossref.org/works/10.1002%2FDA.1078

21 January 2018

Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder.

1 reference

https://api.crossref.org/works/10.1002%2FDA.1078

21 January 2018

Subsyndromal symptoms in bipolar disorder. A comparison of standard and low serum levels of lithium

1 reference

https://api.crossref.org/works/10.1002%2FDA.1078

21 January 2018

The duration, nature and recurrence rate of brief depressions

1 reference

https://api.crossref.org/works/10.1002%2FDA.1078

21 January 2018

Special issues in trial design and use of placebo in bipolar illness

1 reference

https://api.crossref.org/works/10.1002%2FDA.1078

21 January 2018

National Institute of Mental Health Workshop Report on the Treatment of Bipolar Disorder

1 reference

https://api.crossref.org/works/10.1002%2FDA.1078

21 January 2018

The inventory for depressive symptomatology (IDS): Preliminary findings

1 reference

https://api.crossref.org/works/10.1002%2FDA.1078

21 January 2018

Contingent tolerance to the anticonvulsant effects of carbamazepine: relationship to loss of endogenous adaptive mechanisms

1 reference

https://api.crossref.org/works/10.1002%2FDA.1078

21 January 2018

Identifiers

10.1002/DA.1078

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43869831&oldid=2104052034"